The DOI matches its Crossref record.
A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee
Open accessAbstract
Introduction: AMG 108 is a fully human, immunoglobulin subclass G2 (IgG2) monoclonal antibody that binds the human interleukin-1 (IL-1) receptor type 1, inhibiting the activity of IL-1a and IL-1b. In preclinical studies, IL-1 inhibition was shown to be beneficial in models of osteoarthritis (OA). The purpose of this two-part study was to evaluate the safety and pharmacokinetics (PK; Part A) and clinical effect (Part B) of AMG 108 in a double-blind, placebo-controlled, multiple-dose study in patients with OA of the knee. Methods: In Part A, patients received placebo or AMG 108 subcutaneously (SC; 75 mg or 300 mg) or intravenously (IV; 100 mg or 300 mg) once every 4 weeks for 12 weeks; in Part B, patients received placebo or 300 mg AMG 108 SC, once every 4 weeks for 12 weeks. The clinical effect of AMG 108 was measured in Part B by using the Western Ontario and McMaster Universities (WOMAC) osteoarthritis index pain score. Results: In Part A, 68 patients were randomized, and 64 received investigational product. In Part B, 160 patients were randomized, and 159 received investigational product. AMG 108 was well tolerated. Most adverse events (AEs), infectious AEs, serious AEs and infections, as well as withdrawals from the study due to AEs occurred at similar rates in both active and placebo groups. One death was reported in an 80-year-old patient (Part A, 300 mg IV AMG 108; due to complications of lobar pneumonia). AMG 108 serum concentration-time profiles exhibited nonlinear PK. The AMG 108 group in Part B had statistically insignificant but numerically greater improvement in pain compared with the placebo group, as shown by the WOMAC pain scores (median change, -63.0 versus -37.0, respectively). Conclusions: The safety profile of AMG 108 SC and IV was comparable with placebo in patients with OA of the knee. Patients who received AMG 108 showed statistically insignificant but numerically greater improvements in pain; however, minimal, if any, clinical benefit was observed. Trial Registration: This study is registered with ClinicalTrials.gov with the identifier NCT00110942.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Glyn-Jones, S., Palmer, A. J. R., Agricola, R., Price, A. J., Vincent, T. L., Weinans, H., & Carr, A. J. (2015) · The Lancet · doi:10.1016/s0140-6736(14)60802-3 · Cited by 3,151
Osteoarthritis: A disease of the joint as an organ
Loeser, R. F., Goldring, S. R., Scanzello, C. R., & Goldring, M. B. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34453 · Cited by 3,076
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,768
Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis
Robinson, W. H., Lepus, C. M., Wang, Q., Raghu, H., Mao, R., Lindstrom, T. M., & Sokolove, J. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.136 · Cited by 1,438
The role of synovitis in osteoarthritis pathogenesis
Scanzello, C. R., & Goldring, S. R. (2012) · Bone · doi:10.1016/j.bone.2012.02.012 · Cited by 1,302
Synovial inflammation in osteoarthritis progression
Sanchez-Lopez, E., Coras, R., Torres, A., Lane, N. E., & Guma, M. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00749-9 · Cited by 1,041
The role of interleukin-1 in general pathology
Kaneko, N., Kurata, M., Yamamoto, T., Morikawa, S., & Masumoto, J. (2019) · Inflammation and Regeneration · doi:10.1186/s41232-019-0101-5 · Cited by 617
Cytokines and Chemokines Involved in Osteoarthritis Pathogenesis
Molnar, V., Matišić, V., Kodvanj, I., Bjelica, R., Jeleč, Ž., Hudetz, D., Rod, E., Čukelj, F., Vrdoljak, T., Vidović, D., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179208 · Cited by 615
Treating inflammation by blocking interleukin-1 in humans
Dinarello, C. A., & van der Meer, J. W. M. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.10.008 · Cited by 549
Current research on pharmacologic and regenerative therapies for osteoarthritis
Zhang, W., Ouyang, H., Dass, C. R., & Xu, J. (2016) · Bone Research · doi:10.1038/boneres.2015.40 · Cited by 495
Obesity, Inflammation, and Immune System in Osteoarthritis
Nedunchezhiyan, U., Varughese, I., Sun, A. R., Wu, X., Crawford, R., & Prasadam, I. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.907750 · Cited by 466
Emerging pharmaceutical therapies for osteoarthritis
Latourte, A., Kloppenburg, M., & Richette, P. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-00518-6 · Cited by 418
Therapeutic options for targeting inflammatory osteoarthritis pain
Conaghan, P. G., Cook, A. D., Hamilton, J. A., & Tak, P. P. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0221-y · Cited by 405
Liang, Y., Xu, X., Li, X., Xiong, J., Li, B., Duan, L., Wang, D., & Xia, J. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c10458 · Cited by 391
Interleukin-1β signaling in osteoarthritis – chondrocytes in focus
Jenei-Lanzl, Z., Meurer, A., & Zaucke, F. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2018.10.005 · Cited by 387
Karsdal, M. A., Michaelis, M., Ladel, C., Siebuhr, A. S., Bihlet, A. R., Andersen, J. R., Guehring, H., Christiansen, C., Bay-Jensen, A. C., & Kraus, V. B. (2016) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2016.07.017 · Cited by 381
The IL-1 family of cytokines and receptors in rheumatic diseases
Dinarello, C. A. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0277-8 · Cited by 366
Senescent cells and osteoarthritis: a painful connection
Jeon, O. H., David, N., Campisi, J., & Elisseeff, J. H. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95147 · Cited by 356
Cartilage-targeting drug delivery: can electrostatic interactions help?
Bajpayee, A. G., & Grodzinsky, A. J. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.210 · Cited by 325
Recent advances in the treatment of osteoarthritis
Grässel, S., & Muschter, D. (2020) · F1000Research · doi:10.12688/f1000research.22115.1 · Cited by 307
Metabolic triggered inflammation in osteoarthritis
Wang, X., Hunter, D., Xu, J., & Ding, C. (2015) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2014.10.002 · Cited by 305
Structural Basis of IL-1 Family Cytokine Signaling
Fields, J. K., Günther, S., & Sundberg, E. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01412 · Cited by 299
Disease-modifying therapeutic strategies in osteoarthritis: current status and future directions
Cho, Y., Jeong, S., Kim, H., Kang, D., Lee, J., Kang, S.-B., & Kim, J.-H. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00710-y · Cited by 296
Anakinra Therapy for Non-cancer Inflammatory Diseases
Cavalli, G., & Dinarello, C. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01157 · Cited by 292
Interleukin-1 function and role in rheumatic disease
Schett, G., Dayer, J.-M., & Manger, B. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.166 · Cited by 279
Osteoarthritis year in review 2021: biology
Jiang, Y. (2022) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2021.11.009 · Cited by 262
The NLRP3 inflammasome in alcoholic and nonalcoholic steatohepatitis
Knorr, J., Wree, A., Tacke, F., & Feldstein, A. E. (2020) · Seminars in Liver Disease · doi:10.1055/s-0040-1708540 · Cited by 99
Metadata
- Authors
- Cohen, S. B., Proudman, S., Kivitz, A. J., Burch, F. X., Donohue, J. P., Burstein, D., Sun, Y.-N., Banfield, C., Vincent, M. S., Ni, L., & Zack, D. J.
- Venue
- Arthritis Research & Therapy
- Published
- 2011-07-29
- Volume
- 13
- Issue
- 4
- Pages
- R125-R125
- ISSN
- 1478-6354 (ISSN-L)
- OpenAlex
- W2120236484
- Cited by
- 246
- References
- 0
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.